These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 6395527

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
    Saletu B, Schulz H, Herrmann WM, Anderer P, Shrotriya RC, Vanbrabant E.
    Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889
    [Abstract] [Full Text] [Related]

  • 26. [A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers].
    Nobuhara K.
    Seishin Shinkeigaku Zasshi; 1993 Sep; 95(5):392-416. PubMed ID: 8356168
    [Abstract] [Full Text] [Related]

  • 27. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).
    Saletu B, Anderer P, Wolzt M, Nosiska D, Assandri A, Noseda E, Nannipieri F, Saletu-Zyhlarz GM.
    Neuropsychobiology; 2009 Sep; 59(2):110-22. PubMed ID: 19365151
    [Abstract] [Full Text] [Related]

  • 28. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.
    Saletu-Zyhlarz GM, Anderer P, Wolzt M, Semlitsch HV, Assandri A, Nessi P, Nannipieri F, Rosini S, Saletu B.
    Neuropsychobiology; 2009 Sep; 59(2):100-9. PubMed ID: 19365150
    [Abstract] [Full Text] [Related]

  • 29. Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in age-associated memory impairment.
    Semlitsch HV, Anderer P, Saletu B, Hochmayer I.
    Neuropsychobiology; 2009 Sep; 24(1):49-56. PubMed ID: 2132641
    [Abstract] [Full Text] [Related]

  • 30. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA, Pichel V, Pérez P, Laredo M, Corzo D, Zas R, Fernández-Novoa L, Sempere JM, Díaz J, Cacabelos R.
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [Abstract] [Full Text] [Related]

  • 31. Acute and subacute CNS effects of milacemide in elderly people: double-blind, placebo-controlled quantitative EEG and psychometric investigations.
    Saletu B, Grünberger J, Linzmayer L.
    Arch Gerontol Geriatr; 1986 Oct; 5(3):165-81. PubMed ID: 3541816
    [Abstract] [Full Text] [Related]

  • 32. Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses.
    Saletu B, Grünberger J, Volavka J, Berner P.
    Arzneimittelforschung; 1979 Oct; 29(4):700-4. PubMed ID: 582772
    [Abstract] [Full Text] [Related]

  • 33. [Analytic study on EEG features of aging with/without psychiatric disorders: focussing at the alterations in the EEGs of the healthy, depressive and demented elderlies].
    Saito N.
    Seishin Shinkeigaku Zasshi; 1995 Oct; 97(10):801-24. PubMed ID: 8552725
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of pharmacodynamic properties of psychotropic drugs: quanitative EEG, psychometric and blood level investigations in normals and patients.
    Saletu B, Grünberger J.
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Jan; 12(1):45-58. PubMed ID: 419165
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Demonstration of bencyclane effects in a clinico-pharmacologic vigilance model].
    Herrmann WM, Kern U.
    Z Gerontol; 1984 Jan; 17(5):261-70. PubMed ID: 6395526
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Classification and determination of cerebral biovailability of psychotropic drugs by quantitative "pharmaco-EEG" and psychometric investigations (studies with AX-A411-BS).
    Saletu B, Grünberger J, Linzmayer L.
    Int J Clin Pharmacol Biopharm; 1977 Oct; 15(10):449-59. PubMed ID: 21853
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R.
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.